Jewell Named Associate Editor of Regenerative Medicine

University of Maryland Minta Martin Professor of Engineering and MPower Professor Christopher M. Jewell was recently named an associate editor of Nature Portfolio Journal Regenerative Medicine. This open-access journal publishes high-quality research focused on new ways to help the human body repair, replace, restore, and regenerate damaged tissues and organs.

In addition to his appointment in UMD’s Fischell Department of Bioengineering, Jewell is a research biologist with the U.S. Department of Veterans Affairs, an affiliate of the University of Maryland School of Medicine, and a Fischell Institute Fellow with the UMD Robert E. Fischell Institute for Biomedical Devices. Jewell’s work has been supported by more than $25 million in funding, resulting in over 120 manuscripts and patents, including papers in ACS Nano, Cell Reports, Nature, Nature Biotechnology, Nature Materials, PNAS, Trends in Immunology, and others. He is a Fellow of the Biomedical Engineering Society, the American Institute for Medical and Biological Engineering, the Controlled Release Society, and the Alliance for Cancer Gene Therapy.

Jewell was previously awarded the White House’s Presidential Early Career Award for Scientists and Engineers (PECASE), as well as the Damon Runyon-Rachleff Innovator Award, and the Outstanding Lecturership in Drug Delivery Award from the Materials Research Society.

At the University of Maryland, Jewell heads the Immune Engineering Lab, where he and his lab members address fundamental questions of how nanotechnology, polymers, and other advanced technologies interact with the immune system. Jewell and his team work on parallel projects aimed at developing next generation treatments for cancers and autoimmune diseases.

Prior to his appointment at the University of Maryland, Jewell completed his postdoctoral training at MIT and Harvard. He received his Ph.D. from the University of Wisconsin – Madison before joining the Boston Consulting Group in New York, where he worked in research and development strategy with global pharmaceutical companies.

Published October 20, 2022